Successful Lorlatinib Rechallenge After Severe Drug-Induced Psychosis in ALK-Positive Metastatic NSCLC: A Case Report.

Thumbnail Image

Files

Successful Lorlatinib Rechallenge After Severe Drug-Induced Psychosis in ALK-Positive Metastatic NSCLC A Case Report. .pdf (499.16 KB)

Embargo End Date

ICR Authors

Cartwright, Elizabeth

Authors

John, A
Vick, J
Sarker, S
Middleton, E
Cartwright, E
Manickavasagar, T
McMahon, D
Tokaca, N
Popat, S

Document Type

Journal Article

Date

2024-07-01

Date Accepted

2024-05-12

Abstract

Neurocognitive adverse events (NAEs) have been reported in up to 60% of patients on lorlatinib, a potent central nervous system-active ALK inhibitor. Manifestations may include psychotic, mood, speech, and cognitive symptoms. Current guidance recommends permanent discontinuation of lorlatinib in cases of grade IV NAEs. Here, we report a case of successful rechallenge of dose-reduced lorlatinib after recovery of grade IV psychosis in a patient with ALK-positive NSCLC.

Citation

JTO Clinical and Research Reports, 2024, 5 (7), pp. 100689 -

DOI

10.1016/j.jtocrr.2024.100689
10.1016/j.jtocrr.2024.100689

URI

https://repository.icr.ac.uk/handle/internal/6354

Rights

https://creativecommons.org/licenses/by-nc-nd/4.0/

Source Title

JTO Clinical and Research Reports

Publisher

ELSEVIER

ISSN

2666-3643

eISSN

2666-3643
2666-3643

Collections

Clinical Studies

Research Team

Notes